• BridgeBio reported Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia, published in NEJM, with data already presented at ICCBH 2026.
• The trial showed faster growth versus placebo, with gains in overall stature measures over 52 weeks.
• Results also indicated improved body proportionality versus placebo, a key differentiator for positioning against existing therapies.
• Safety profile was described as favorable, with no treatment-related serious adverse events or discontinuations.
• Regulatory filings are targeted for 2H 2026 in Europe, Q3 2026 in the US, with a US launch anticipated in early to mid 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606281600PRIMZONEFULLFEED9753618) on June 28, 2026, and is solely responsible for the information contained therein.